Regulatory
FDA Halts Regenxbio’s Hunter Syndrome Gene Therapy Again Over Spine Scan Findings
The agency paused testing of RGX-121 after spinal MRI abnormalities turned up in patients treated years ago — the second clinical hold on a Regenxbio program in 2026.